

Amendments to the Claims

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1 (Currently amended). ~~A~~ An isolated peptide originating from mammalian ~~IL1 β~~ or TNF α cytokines, which has consisting of a sequence with more than 80% amino acid ~~homology~~ identity to SEQ ID NO:5 ~~one of the following peptides of human IL1 β or TNF α cytokines:~~

~~140 DYLDFAESGQVY 150 (SEQ ID NO:5);
3 VKSLNCTLRDSQQKSL 18 (SEQ ID NO:7);
45 SFVQGEESNDKIP 57 (SEQ ID NO:8);
89 NYPKKKMEKRFVFNKIEI 106 (SEQ ID NO:9);
121 YISTSQAENMPVFLG 135 (SEQ ID NO:4); and
143 ITDFTMQFVSS 153 (SEQ ID NO:10).~~

Claim 2 (Cancelled).

3 (Currently amended). A peptide according to claim 1, wherein the peptide is the human TNF α cytokine peptide consisting of the sequence ~~is~~ DYLDFAESGQVY (SEQ ID NO:5)

Claims 4-9 (Cancelled).

10 (Previously Presented). A derivative of the peptide according to claim 1.

Claim 11 (Cancelled).

12 (Currently Amended). A derivative of a peptide as defined in claim 1 by cyclization, stereochemical modification

(use of D series amino acids) or functionalization ~~(such as acylation)~~ of one or more amino acids of said peptide.

13 (Currently Amended). An isolated immunogenic compound ~~characterized in that it comprises~~ comprising: (a) a peptide consisting of a peptide as defined in according to claim 1; and (b) a heterologous carrier protein that increases the immunogenicity of the peptide in (a) ~~it being understood that it comprises no other epitopes of said cytokine and in that it is capable of generating in a subject antibodies recognizing the native cytokine.~~

14 (Previously presented). An immunizing composition, comprising the immunogenic compound of claim 13 and an adjuvant.

Claims 15 and 16 (Cancelled).

17 (Currently Amended). A pharmaceutical composition which contains at least one peptide as defined in claim 1 as active ingredient and a pharmaceutically acceptable excipient.

Claim 18-20 (Cancelled).

21 (Withdrawn-Currently Amended). A method for the treatment or prevention of diseases associated with the pathogenic overproduction of ~~IL1 β or TNF α~~ , comprising administering to a patient in need thereof a peptide as defined in claim 1 to treat or inhibit the disease associated with the pathogenic overproduction of ~~IL1 β or TNF α~~ .

22 (New). The derivative of claim 12, wherein the functionalization is acylation.